MediWound Ltd.
MediWound Ltd. is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The company specializes in the development, production, and commercialization of rapid and effective biologics that enhance existing standards of care, improve patient experiences, and reduce costs and unnecessary surgeries.
MediWound Ltd.
42 Hayarkon Street, Yavne 8122745, Israel
What We Do
A topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and/or full-thickness thermal burns without harming viable tissue. Approved in over 40 countries, including the United States, European Union, and Japan. Recently, the FDA approved NexoBrid for use in pediatric patients.
A bioactive, multimodal debridement therapy for the treatment of chronic and other hard-to-heal wounds, currently in advanced stages of clinical development. It is a concentrate of proteolytic enzymes enriched with bromelain for topical applications. The Phase 3 study for EscharEx is set to commence in the second half of 2024.
An innovative topical biological drug currently in development to address the treatment needs of low-risk Basal Cell Carcinoma (BCC). In a Phase I/II trial, MW005 was shown to be safe and effective for BCC treatment, with positive initial data indicating complete histological clearance of target lesions.
Key People
Robert J. Snyder
Chief Medical Officer
Hani Luxenburg
Chief Financial Officer
News & Updates
MediWound Ltd. announced that the Company will release its financial results for the third quarter ended September 30, 2022 on November 15, 2022.
MediWound Ltd. announced the establishment of a Strategic Advisory Board (SAB) to guide the Company with experienced executives.
Positive clinical data from the Company’s EscharEx® Phase 2 trials was featured in presentations at the SAWC Fall 2022 Conference.
The U.S. FDA has approved NexoBrid® for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns.
MediWound announced it has gained marketing approval of NexoBrid® in India, with plans for commercialization in the first half of 2023.